Hypothesis

Aging-induced increase in nucleosome repeat length (NRL) alters chromatin accessibility, leading to preferential release of ~175 bp cfDNA fragments enriched for hypomethylated LINE-1 elements. These fragments act as endogenous TLR9 ligands, triggering a chronic low‑grade inflammatory state (inflammaging) that in turn accelerates epigenetic drift and further NRL expansion, creating a positive feedback loop.

Mechanistic Rationale

1. NRL expansion shifts fragmentation patterns – As reported, aging increases NRL, moving nucleosome signals from heterochromatin (B1) to euchromatin (A1/A2) regions [[https://pmc.ncbi.nlm.nih.gov/articles/PMC6351822/]]. Longer NRL means nucleosomes are spaced farther apart, making linker DNA more accessible to nucleases during apoptosis/necrosis. This yields a higher proportion of mononucleosome‑sized cfDNA (~175 bp) and reduces long fragments, exactly as observed in plasma [[https://pmc.ncbi.nlm.nih.gov/articles/PMC11318736/]].
2. Hypomethylated LINE-1 enrichment – Over 50% of age‑related differentially methylated CpGs reside in LINEs [[https://pmc.ncbi.nlm.nih.gov/articles/PMC11318736/]]. Hypomethylation increases LINE‑1 transcription and also makes their DNA more susceptible to nuclease cleavage, enriching these elements in the cfDNA pool. Hypomethylated CpG motifs within LINE‑1 are known TLR9 agonists [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12905613/]].
3. TLR9 activation propagates inflammaging – cfDNA‑TLR9 signaling in myeloid cells triggers NF‑κB driven production of IL‑6, TNF‑α, and type I interferons, establishing a sterile inflammatory milieu. Chronic TLR9 stimulation has been shown to exacerbate age‑related phenotypes in mouse models [[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833446/]].
4. Feedback to epigenetics – Inflammatory cytokines can induce oxidative stress and alter DNMT/TET activity, promoting further methylation loss at LINE‑1 and other repeat elements, thereby increasing the cfDNA inflammatory load.

Testable Predictions

• Prediction 1: Individuals with higher plasma NRL‑derived cfDNA fraction (ratio of 175‑bp to >500‑bp fragments) will exhibit elevated serum TLR9‑dependent cytokines (IFN‑α, IL‑6) independent of total cfDNA concentration.
• Prediction 2: Pharmacological inhibition of TLR9 (e.g., with ODN TTAGGG antagonists) will reduce inflammaging markers and slow the rate of NRL increase measured by MNase‑seq of peripheral blood mononuclear cells over 6 months.
• Prediction 3: LINE‑1 hypomethylation in cfDNA will correlate positively with both NRL expansion and TLR9 activation scores across cohorts.

Experimental Design

1. Cross‑sectional cohort (n=300, ages 20‑80): Plasma cfDNA sequenced for fragment size distribution and methylation at LINE‑1 CpGs; parallel measurement of NRL in PBMC MNase‑seq; serum cytokine panel. Use multivariable regression to test if NRL‑derived cfDNA fraction predicts cytokine levels after adjusting for age, total cfDNA, and cell‑type deconvolution.
2. Intervention trial (n=60, aged 60‑75, randomized to TLR9 antagonist vs placebo for 6 months): Primary outcome change in NRL‑derived cfDNA fraction; secondary outcomes include LINE‑1 methylation, inflammaging cytokines, and epigenetic age (GrimAge).
3. Mechanistic validation in vitro: Treat primary human neutrophils with recombinant MNase to generate cfDNA fractions; assess TLR9 activation in HEK‑Blue™ TLR9 reporter cells; manipulate NRL via histone H1 knockdown/overexpression and repeat assays.

Potential Confounds & Mitigation

• Acute infection or tissue injury can spike cfDNA and TLR9 ligands. Exclude participants with recent illness, CRP >5 mg/L, or adjust statistically.
• Cell‑type specific apoptosis rates may independently affect cfDNA composition. Include neutrophil and epithelial cell proportion estimates from methylation‑based deconvolution as covariates.
• Genetic variation in TLR9 (e.g., rs187084) could influence response. Genotype and stratify analyses.

Implications

If validated, this hypothesis reframes cfDNA fragmentation not merely as a biomarker but as a mechanistic driver of inflammaging, suggesting that targeting nucleosome spacing or TLR9 signaling could decouple epigenetic aging from inflammatory damage, offering a novel avenue for aging intervention trials.